Tofacitinib in Juvenile Idiopathic Arthritis

ConditionJuvenile Idiopathic Arthritis (JIA)

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeUp to 18

SponsorConsorci Sanitari de l'Alt Penedès i Garraf

About this trial

This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Patients with JIA

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

Tofacitinib
Drug
Patients received tofacitinib for the treatment of juvenile idiopathic arthritis (JIA).

Treatment groups

58 Participants

are divided into 1 treatment group

Group A: Tofacitinib1 intervention

Trial outcomes

Primary outcomes

JADAS-10

Change in the Juvenile Arthritis Disease Activity Score (JADAS-10) score at 12 months of treatment with tofacitinib. Range score: 0 to 10, the less score the better

Time frame

Baseline and 12 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Consorci Sanitari de l'Alt Penedès i Garraf

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: